Cheaper Alternative to Repatha: Cost vs PCSK9 Options
Repatha costs about $6,168 a year (WAC). Compare Praluent, inclisiran, statins and ezetimibe prices to find a cheaper LDL-lowering option.
Evolocumab
31 source-based articles maintained by the HealthRX.com Editorial Team.
31articles
6topic areas covered
May 27, 2026latest review
Evolocumab library
Showing 31 of 31 clinical reviews.
Does Aetna (CVS Health) Cover Repatha (Evolocumab)?
A clinical guide to Aetna's Repatha coverage policy: prior authorization criteria, step therapy requirements, formulary tier, appeal process, and cost-assistance options for evolocumab.
Does Blue Cross Blue Shield (Federated) Cover Repatha (Evolocumab)?
A clinical and practical guide to Blue Cross Blue Shield Federated coverage for Repatha (evolocumab), including prior authorization criteria, step therapy requirements, appeal strategies, and cost options for 2024.
Does Humana Cover Repatha (Evolocumab)? Coverage, Prior Auth, and Appeals
A complete guide to Humana coverage for Repatha (evolocumab), including prior authorization criteria, step therapy requirements, formulary tier, appeal strategies, and manufacturer savings options.
Does Kaiser Permanente Cover Repatha (Evolocumab)?
A clinical guide to Kaiser Permanente's Repatha (evolocumab) coverage: formulary tier, prior authorization criteria, step therapy requirements, appeals process, and patient savings options.
Does Medicare Advantage Cover Repatha (Evolocumab)?
Medicare Advantage plans cover Repatha (evolocumab) through Part D for familial hypercholesterolemia and established cardiovascular disease, but prior authorization and step therapy are near-universal hurdles. Here is what determines approval.
Does TRICARE Cover Repatha (Evolocumab)? Coverage, Prior Auth, and Appeals Explained
A complete guide to TRICARE coverage for Repatha (evolocumab), including prior authorization criteria, step therapy requirements, formulary tier, and how to appeal a denial. prepared by the HealthRX.com Editorial Team.
Repatha (Evolocumab) Adult Dosing for Ages 30 to 49: Schedule, Administration, and What to Expect
A guide to Repatha (evolocumab) dosing for adults aged 30 to 49, covering FDA-approved schedules, injection technique, missed-dose handling, and what remains individualized versus standardized.
Repatha (Evolocumab) Complete Drug-Drug Interaction Profile
A clinician-grade review of evolocumab (Repatha) drug-drug interactions, covering statins, ezetimibe, warfarin, immunosuppressants, and more, with PubMed-cited evidence.
Repatha (Evolocumab) Future Formulations and Pipeline: What Comes Next for PCSK9 Therapy
A clinical review of evolocumab's mechanism of action, the FOURIER trial evidence base, and the next-generation PCSK9 pipeline including oral inhibitors, siRNA, and gene-editing approaches.
Repatha (Evolocumab) Manufacturing, Supply & Shortage History
A clinical deep-dive into Repatha's manufacturing process, supply chain structure, and documented shortage events, with FDA-sourced evidence and clearly flagged areas needing verification.
Repatha (Evolocumab) Missed-Dose Protocol: What to Do and When
Missed Repatha? Find the instructions for every-two-week and monthly dosing, with seven-day timing examples, storage guidance and next steps.
Repatha (Evolocumab) Monitoring for Adults Age 30 to 49
Evidence-based monitoring schedule for evolocumab (Repatha) in adults aged 30 to 49, including lipid panels, liver function, injection-site checks, and PCSK9 inhibitor safety labs.
Repatha (Evolocumab) Pharmacokinetics: Absorption, Distribution, Metabolism, and Elimination
A clinician-grade review of evolocumab (Repatha) pharmacokinetics covering ADME, target-mediated disposition, half-life, dosing intervals, and special-population considerations with PubMed-cited evidence.
Repatha (Evolocumab): History and Development
A complete timeline of evolocumab from the 2003 discovery of PCSK9 through FDA approval, the FOURIER outcomes trial, and label expansions. Mechanism, clinical evidence, and pricing milestones.
Repatha Appetite & Cravings Changes: What the Evidence Actually Shows
Does evolocumab (Repatha) affect appetite or food cravings? A clinician-level review of FOURIER trial data, PCSK9 biology, lipid-appetite signaling, and what patients and prescribers should expect.
Repatha Cancer Risk Signal Review: What the Evidence Actually Shows
A analysis of the evolocumab (Repatha) cancer risk signal, covering FOURIER trial data, long-term extension studies, mechanistic hypotheses, and current FDA and guideline positions on PCSK9 inhibitor safety.
Repatha Hair and Skin Changes: What the Clinical Evidence Actually Shows
A guide to evolocumab (Repatha) hair and skin effects, covering FOURIER trial data, PCSK9 biology, real-world reports, and clinical management steps.
Repatha Liver Function Impact: What the Clinical Evidence Actually Shows
A physician-level review of evolocumab (Repatha) and liver function: ALT/AST patterns, hepatotoxicity risk, monitoring requirements, and what FOURIER and post-marketing data tell clinicians managing patients on PCSK9 inhibitor therapy.
Repatha Mental Health and Mood Impact: What the Evidence Actually Shows
Does evolocumab (Repatha) affect mood, cognition, or mental health? A trial-level analysis of FOURIER, EBBINGHAUS, and post-market safety data for patients and clinicians.
Repatha Monitoring Schedule: Labs & Exams You Need on Evolocumab
Complete evolocumab (Repatha) monitoring schedule covering lipid panels, liver function tests, injection-site checks, and long-term follow-up. Evidence-based timelines from FOURIER, ACC/AHA, and NLA guidelines.
Repatha Off-Label Uses With Evidence Levels: What the Data Actually Show
A guide to evolocumab (Repatha) off-label uses, graded by evidence level, covering statin-intolerant patients, heart failure, kidney disease, post-transplant dyslipidemia, and more.
Repatha Patent Field & Generic Timeline: What to Expect and When
A clinician-level breakdown of evolocumab (Repatha) patent expiration dates, biosimilar entry timelines, PCSK9 mechanism, FOURIER trial outcomes, and what generic competition means for patient access and pricing.
Repatha Plateau & Non-Response Troubleshooting: A Clinical Guide to Evolocumab LDL Failure
Why your patient's LDL-C isn't dropping on evolocumab (Repatha), and what to do about it. Covers pseudo-resistance, true non-response, add-on options, and re-challenge protocols with primary-literature citations.
Repatha Pre-Surgery Hold Window: What Clinicians Need to Know About Evolocumab Perioperative Management
A clinician-focused guide to the evolocumab (Repatha) pre-surgery hold window, covering pharmacokinetics, guideline recommendations, FOURIER trial data, and practical perioperative protocols for patients on PCSK9 inhibitor therapy.
Repatha Rebound Effects When Stopping: What the Evidence Actually Shows
Stopping evolocumab (Repatha) does not cause a rebound LDL spike above pre-treatment baseline. LDL rises back to baseline over 8 to 12 weeks as PCSK9 inhibition wears off. Here is what the clinical data say about discontinuation, and how to manage it.
Repatha Restarting After Acute Illness: A Clinical Guide to Evolocumab Interruption and Re-initiation
When and how to restart Repatha (evolocumab) after acute illness, hospitalization, or surgery. Covers the evidence on LDL rebound, missed-dose pharmacokinetics, and step-by-step re-initiation protocol.
Repatha Sleep Architecture Impact: What the Evidence Actually Shows
Does evolocumab (Repatha) affect sleep architecture? A deep review of PCSK9 inhibitor neurobiology, CNS cholesterol metabolism, clinical trial sleep data, and practical monitoring guidance for clinicians and patients.
Repatha Storage, Stability & Shelf Life: The Complete Clinical Guide
Everything clinicians and patients need to know about evolocumab (Repatha) storage requirements, shelf life, cold-chain management, and what to do when the product is exposed to adverse conditions.
Stopping Repatha: LDL Changes and Questions Before Restarting
Plan a Repatha stop or restart discussion using injection dates, LDL results and study evidence, with a follow-up record and timing distinctions.
Switching to or from Repatha (Evolocumab): Protocols, Timing, and What the Evidence Shows
Evidence-based guide to switching between Repatha (evolocumab) and other PCSK9 inhibitors or lipid-lowering therapies, including alirocumab, inclisiran, bempedoic acid, and statins.